Validation of RCC Predicting Model With Emulated-target Trial

NCT07117227 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 4700

Last updated 2026-04-14

No results posted yet for this study

Summary

This single-center study utilizes real-world data (2012-2024) from 4700 renal cell carcinoma (RCC) patients at Peking University Third Hospital to: (1) Develop and validate a prognostic prediction model specifically for RCC patients, including those with venous tumor thrombus (VTT); (2) Compare the performance of this new model against existing RCC prediction models in both the overall RCC cohort and the VTT subgroup; (3) Employ an emulated target trial (ETT) methodology to evaluate whether risk-stratified treatment based on the prediction model (grouping patients as high/medium/low risk) improves survival outcomes .

Conditions

  • Renal Cell Carcinoma (Kidney Cancer)
  • Renal Cell Carcinoma (RCC)
  • Tumor Thrombus
  • Prognosis
  • Prognostic Cancer Model
  • Real World Study
  • Observational Study

Interventions

PROCEDURE

Model-guided adjuvant treatment

Initiation of standard adjuvant treatment within 12 weeks after surgery.

PROCEDURE

No adjuvant treatment

No initiation of adjuvant ICIs, radiotherapy, or targeted therapy at any point during follow-up prior to disease progression.

Sponsors & Collaborators

  • Peking University Third Hospital

    lead OTHER

Principal Investigators

  • Yongyue Wei, master · Peking University Health Science Center

  • Shudong Zhang, master · Peking University Third Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2027-02-01
Completion
2027-08-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07117227 on ClinicalTrials.gov